Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs Zscaler Inc (ZS) Price & Performance

ResMed Inc.Trade
Zscaler IncTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs Zscaler Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while Zscaler Inc trades at $166 (market cap $27.08B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.2% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.

RMDZS
Market Cap
$31.73B$27.08B
Sector
HealthTechnology
52-Week High
$283.28$336.27
52-Week Low
$182.82$118.05
Enterprise Value
$31.08B$25.47B
Dividend Yield
1.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.

Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.

Zscaler Inc

Zscaler (ZS) trades at $161.94, down 4.63% today, reflecting bearish technical signals despite strong quarterly earnings beats. Revenue growth remains robust at 25% year-over-year in Q4 2026, though net income margins are negative. The stock faces headwinds from slowing growth guidance for FY2027 and elevated valuation multiples, with a consensus price target of $204.88 suggesting 26% upside. Recent news highlights AI security product launches and conference presentations.

Outlook is mixed: analyst sentiment is overwhelmingly bullish (79% buy ratings), but execution risks and decelerating top-line growth cloud near-term performance. Investment opportunity hinges on AI-driven cybersecurity demand offsetting margin pressures, while risks include competitive threats and capital expenditure increases impacting cash flow.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS